AbCellera is a biotechnology company that develops next-generation antibody therapeutics to improve the lives of patients. AbCellera's single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, deep computation, artificial intelligence, and laboratory automation. Ultra-deep screening of single B cells allows unprecedented access to natural immune responses, enabling rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans. AbCellera's partners include leading biotechnology companies, global health organizations, and many of the top 10 biopharmaceutical companies. AbCellera was founded in 2012 by Carl Hansen, Véronique Lecault, and Kevin Heyries.
Highest paying job titles at AbCellera Biologics include Process Development Scientist, Bioinformatics Scientist, and Pilot